Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
Secarna's managing director Jonas Renz talks about the company's antisense platform and partnering strategy.
Emerging Company Profile: Syndesi Therapeutics, a new biotech built upon research from UCB, aims to develop novel drugs for neurodegenerative conditions like Alzheimer's disease; the company has a stream of big name investors such as J&J Innovation and Novo Holdings.
Mark Rowan, associate director of business development at Genentech, talks to Scrip at BIO-Europe Spring 2018 about the company's recent technology deals with DiCE Molecules and FinnGen.
Kara Bortone, head of Johnson & Johnson Innovation's JLABS site in San Diego and interim head of the group's newest incubator site in Belgium, on the benefits of JLABS for the companies involved and the big pharma itself.
Ayala Pharma, which launched in late 2017, has raised $17m via a series A financing round to propel its lead precision cancer therapy into Phase II – an asset it licensed from Bristol-Myers Squibb.
Pekka Simula, CEO of Herantis, a company born from the merger of Hermo Pharma and Laurantis Pharma, talks to Scrip about the group's lead asset in Parkinson's disease.